Drug - Thiazolidinedinones (TZDs)
December 2007
Therapeutic area - Diabetes
Preferred - No PA required | Nonpreferred |
Actos
15 mg, 30 mg, 45 mg |
Avandia
2 mg, 4 mg, 8 mg |
Increased weight gain or fluid retention is expected of either drug, but may constitute a definition of failure. It is possible that a patient will have different fluid-retention responses to the two TZDs. Patients with heart failure should not take either TZD or any combination with a TZD.
Authorization will not be granted if failure is defined as:
Neither of these drugs should be approved for use in patients who have:
See Grandfathering Criteria – which indicate patient specific criteria that would exclude a patient from switching to a preferred drug
Other notes
MHCP Provider Call Center 651-431-2700 or 800-366-5411